Newswise — Machine learning using real-time symptom reports can accurately detect lymphedema, a distressing side effect of breast cancer treatment that is more easily treated when identified early, finds a new study led by NYU Rory Meyers College of Nursing and published in the journal mHealth.
“Using a well-trained classification algorithm to detect lymphedema based on real-time symptom reports is a highly promising tool that may improve lymphedema outcomes,” said Mei R Fu, PhD, RN, FAAN, associate professor of nursing at NYU Meyers and the study’s lead author.
Lymphedema is a build-up of lymph fluid that causes swelling in the arms or legs and is commonly caused by the removal of lymph nodes as part of cancer treatment. It can occur immediately after cancer surgery or as late as 20 years after surgery; a recent study found that more than 41 percent of breast cancer patients experienced lymphedema in their arms within 10 years of their surgery.
Lymphedema is one of the most dreaded adverse effects from breast cancer treatment because of its chronic nature and debilitating symptoms, including arm swelling, heaviness, tightness, achiness, stiffness, burning, and decreased mobility. While there is no cure for lymphedema, early detection and intervention can reduce symptoms and keep it from worsening, although early detection remains a challenge.
“Clinicians often detect or diagnose lymphedema based on their observation of swelling. However, by the time swelling can be observed or measured, lymphedema has typically occurred for some time, which may lead to poor clinical outcomes,” said Fu.
“In our digital era, integrating technology into health care has led to advances in detecting and predicting various medical conditions,” said Yao Wang, PhD, professor of electrical and computer engineering at NYU Tandon School of Engineering and the study’s coauthor.
A type of artificial intelligence, machine learning is of interest to researchers due to its ability to construct algorithms that continually improve predictions and generate automated knowledge through data-driven predictions or decisions with incoming data—in this case, symptom reports. Machine learning is particularly beneficial when there are many relevant factors that are not independent, which is true for lymphedema symptoms.
In this study, the researchers used a web-based tool to collect information from 355 women who had undergone treatment for breast cancer, including surgery. In addition to sharing demographic and clinical information, including whether they had been diagnosed with lymphedema, participants were asked whether they were currently experiencing 26 different lymphedema symptoms.
Statistical and machine learning procedures were performed for data analysis. Five different classification algorithms of machine learning were compared: Decision Tree of C4.5, Decision Tree of C5.0, gradient boosting model, artificial neural network, and support vector machine. The algorithms were also compared with a conventional statistical approach that determines the optimal threshold for the symptom count based on the receiver operating curve.
The researchers found that all five machine learning approaches outperformed the standard statistical approach, and the artificial neural network achieved the best performance for detecting lymphedema. The artificial neural network was 93.75 percent accurate, correctly classifying patients to have true lymphedema cases or non-lymphedema cases based on the symptoms reported.
“Such detection accuracy is significantly higher than that achievable by current and often used clinical methods,” said Fu.
The researchers note that conducting such real-time lymphedema assessment encourages patients to monitor their lymphedema status without having to visit a healthcare professional. Based on patients’ symptoms and resulting risk for lymphedema, the assessment system could alert patients at risk to schedule in-person clinical visits for further evaluation. This may lessen the burden of unnecessary clinical visits on patients and the healthcare system.
“This has the potential to reduce healthcare costs and optimize the use of healthcare resources through early lymphedema detection and intervention, which could reduce the risk of lymphedema progressing to more severe stages,” Fu said.
In addition to Fu and Wang, authors include Chenge Li of NYU Tandon; Zeyuan Qiu of New Jersey Institute of Technology; Deborah Axelrod and Amber A. Guth of NYU School of Medicine and NYU Perlmutter Cancer Center; Joan Scagliola of NYU Perlmutter Cancer Center; Yvette Conley of the University of Pittsburgh School of Nursing; Bradley E. Aouizerat of the Bluestone Center for Clinical Research at NYU College of Dentistry; Jeanna M. Qiu of Harvard University; Gary Yu, Janet H. Van Cleave, and Judith Haber of NYU Meyers; and Ying Kuen Cheung of Columbia University’s Mailman School of Public Health.
This study was supported by National Institutes of Health (NIMHD P60 MD000538-03 and NCI
1R01CA214085-01), Judges and Lawyers for Breast Cancer Alert, Pfizer Independent Grants for Learning & Change (13371953 The-Optimal Lymph-Flow™) and the Pless Center for Nursing Research of NYU Rory Meyers College of Nursing.
About the NYU Rory Meyers College of Nursing
NYU Rory Meyers College of Nursing is a global leader in nursing education, research, and practice. It offers a bachelor of science with a major in nursing, a master of science, post-master’s certificate programs, a doctor of nursing practice degree, and a doctor of philosophy in research theory and development.
MEDIA CONTACTRegister for reporter access to contact details
P60 MD000538-03; 1R01CA214085-01; mHealth, May 2018